Trial Profile
A Retrospective study comparing iSEND with Tumor Mutation Burden (TMB) to predict the clinical outcomes of Nivolumab treatment in patients with advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics; Therapeutic Use
- 08 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer